Jardiance Side Effects: Severity Distribution by Patient Phenotype

How the FDA Classifies Empagliflozin's Adverse Events

The FDA-approved prescribing information for empagliflozin organizes adverse reactions into common, uncommon, and rare categories based on the pooled Phase III development program. Understanding this hierarchy is the fastest way to set accurate patient expectations before the first prescription is written.

What the Prescribing Label States

The current Jardiance label lists genital mycotic infections, urinary tract infections (UTIs), increased urination, and dyslipidemia as adverse reactions with an incidence of at least 2% and exceeding placebo. Volume depletion events (hypotension, syncope, dehydration) appear in a separate warnings section alongside diabetic ketoacidosis, urosepsis, pyelonephritis, and necrotizing fasciitis of the perineum (Fournier gangrene). FDA prescribing information for Jardiance is available at the FDA label repository.

EMPA-REG OUTCOME as the Primary Safety Dataset

EMPA-REG OUTCOME (N=7,020 adults with T2DM and established cardiovascular disease) remains the largest and most cited randomized controlled trial for empagliflozin safety. At a median follow-up of 3.1 years, the trial showed that empagliflozin reduced the risk of the primary composite MACE endpoint and, critically, generated a prospectively collected adverse-event dataset large enough to detect rare events at a frequency of approximately 1 in 1,000. The primary EMPA-REG OUTCOME results were published in the New England Journal of Medicine.

The trial's safety supplement reported genital mycotic infections in 6.4% of empagliflozin-treated patients versus 1.8% of placebo patients (P<0.001), establishing the most statistically strong signal in the trial program. Volume depletion adverse events occurred in 2.2% versus 1.3% (placebo), driven largely by patients on loop diuretics at baseline. Full safety data are published alongside the EMPA-REG OUTCOME primary paper.

Mild-to-Moderate Adverse Events: Phenotype-Specific Incidence

Most patients experience adverse events that are self-limiting or manageable with minor interventions. The phenotype of the patient, however, changes the probability substantially.

Genital Mycotic Infections

Genital mycotic infections represent the highest-frequency adverse event class for empagliflozin. Glucosuria creates a substrate-rich environment for Candida species in the perineum. A pooled analysis of 12 Phase II/III empagliflozin trials published via the FDA's drug-approval documents confirms this mechanism.

Phenotype-specific rates from the EMPA-REG OUTCOME safety analysis:

• Women with a history of prior vaginal candidiasis: estimated 3-fold higher recurrence risk compared to women without prior infection.
• Uncircumcised men: higher absolute rate of balanitis compared to circumcised men, though the absolute difference in the overall trial was modest (approximately 3% vs. 1%).
• Women overall: approximately 10% incidence across pooled Phase III data.
• Men overall: approximately 3.5 to 4% incidence.

Almost all genital mycotic infections are Grade 1 or Grade 2 by Common Terminology Criteria for Adverse Events (CTCAE). Discontinuation rates due to this event in EMPA-REG OUTCOME were below 0.5%. The EMPA-REG safety data are publicly archived at PubMed.

Urinary Tract Infections

The glucosuria hypothesis predicts high UTI rates for all SGLT2 inhibitors, but the clinical trial data for empagliflozin are more nuanced. In EMPA-REG OUTCOME, UTI incidence was 8.1% in the empagliflozin group versus 8.1% in placebo, showing no statistically significant difference. This null UTI result is discussed in the EMPA-REG OUTCOME safety supplement.

Post-market FAERS data tell a different story for severe UTI phenotypes. Women aged over 65, patients with neurogenic bladder, and those with a history of recurrent UTIs show disproportionate representation in FAERS serious UTI reports for the SGLT2 inhibitor class. FAERS data for empagliflozin can be queried through the FDA's FAERS dashboard.

Polyuria and Volume Depletion

Empagliflozin's osmotic diuresis effect typically produces a modest 200 to 400 mL per day increase in urine output during the first two weeks, after which compensatory mechanisms attenuate the effect. The clinical problem concentrates in patients who are already volume-depleted at baseline. In EMPA-REG OUTCOME, patients on three or more antihypertensives at baseline had a 3.3% rate of volume depletion adverse events compared to 1.8% in the overall empagliflozin arm. This subgroup data is available in the EMPA-REG OUTCOME paper and supplementary appendix at NEJM.

Elderly patients (age 75 and older) warrant extra caution. A dedicated subgroup analysis of EMPA-REG OUTCOME participants aged 75 and older found numerically higher rates of volume depletion events, consistent with reduced thirst perception and baseline lower intravascular volume in this age group. Age-stratified subgroup data from EMPA-REG OUTCOME are published at PubMed.

Serious Adverse Events: Risk Stratification by Phenotype

The events that carry the greatest clinical weight are rare in absolute terms but predictable enough to be preventable with correct patient selection.

Diabetic Ketoacidosis

Empagliflozin-associated diabetic ketoacidosis (DKA) is often euglycemic, meaning blood glucose may be below 250 mg/dL at presentation. This atypical presentation delays diagnosis and worsens outcomes. The FDA issued a Drug Safety Communication on euglycemic DKA for the entire SGLT2 inhibitor class in 2015.

Phenotypes at highest DKA risk with empagliflozin:

1. Patients with latent autoimmune diabetes in adults (LADA) or misclassified Type 1 diabetes: Off-label use in insulin-deficient states is the single largest risk factor. A case series in Diabetes Care identified that 70% of SGLT2 inhibitor-associated DKA cases occurred in patients with low or absent endogenous insulin secretion. Published in the ADA's Diabetes Care journal.
2. Patients on very-low-carbohydrate diets: Carbohydrate restriction reduces insulin secretion and increases glucagon, potentiating ketogenesis. Practitioners should counsel patients to temporarily discontinue empagliflozin at least 3 days before elective surgery or during extended fasting. The FDA label explicitly warns about peri-operative DKA risk.
3. Patients with recurrent alcohol use: Alcohol independently promotes ketogenesis. The combination with SGLT2 inhibition carries additive ketogenic risk.
4. Patients undergoing major surgery or acute illness with reduced oral intake: The FDA label recommends holding empagliflozin at least 3 days before scheduled surgery. This recommendation appears in the FDA-approved Jardiance label.

In the pooled EMPA-REG OUTCOME and Phase III development program, adjudicated DKA occurred in 0.1% of empagliflozin-treated patients versus 0.0% of placebo patients. Small absolute difference; large relative consequence per event. Adjudicated DKA event rates are reported in the EMPA-REG OUTCOME paper at NEJM.

Fournier Gangrene (Necrotizing Fasciitis of the Perineum)

Fournier gangrene is a rare but life-threatening polymicrobial infection of the perineal and genital soft tissues. The FDA added a warning for the entire SGLT2 inhibitor class in August 2018 after reviewing 12 cases in FAERS over approximately 5 years of post-market exposure (estimated tens of millions of patient-years). The FDA Drug Safety Communication on Fournier gangrene is available directly.

The estimated background rate of Fournier gangrene in the general diabetic population is approximately 1.6 per 100,000 person-years. Risk phenotypes include:

• Male sex (historical 10:1 male predominance, though SGLT2 inhibitor cases have been more evenly distributed).
• Poorly controlled diabetes (HbA1c above 9%).
• Obesity (BMI above 35 kg/m²).
• Chronic kidney disease stage 3 or above.
• Immunosuppression.

A cohort analysis comparing Fournier gangrene rates in SGLT2 inhibitor users versus non-users is published at PubMed via a JAMA Internal Medicine study.

Urosepsis and Pyelonephritis

Unlike lower-tract UTI, upper-tract infections with empagliflozin carry serious morbidity. The FDA label's warnings section specifically identifies urosepsis and pyelonephritis as post-market findings requiring prompt evaluation. Phenotypes at risk include women with anatomic urinary tract anomalies, patients with indwelling catheters, and those with a history of recurrent complicated UTIs. See the current FDA label for Jardiance.

Renal Adverse Events: A Nuanced Phenotype Story

Empagliflozin produces an initial acute reduction in eGFR of approximately 2 to 4 mL/min/1.73 m² within the first 2 to 4 weeks. This is a hemodynamic, reversible effect related to reduced glomerular hyperfiltration. Over 2 to 3 years, eGFR decline in empagliflozin-treated patients is slower than placebo. The renal outcome data from EMPA-REG OUTCOME are published at NEJM.

The EMPA-KIDNEY Trial

EMPA-KIDNEY (N=6,609 patients with CKD, eGFR 20 to 45 mL/min/1.73 m² or eGFR 45 to 90 with urinary albumin-to-creatinine ratio at least 200 mg/g) tested empagliflozin 10 mg specifically in patients with CKD. The trial was stopped early for efficacy. Empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% (hazard ratio 0.72, 95% CI 0.64 to 0.82, P<0.001). Adverse renal events were not increased. EMPA-KIDNEY primary results are published in the New England Journal of Medicine.

Who Faces Acute Kidney Injury Risk

Volume depletion-mediated AKI is the renal adverse event to monitor, especially in:

• Patients on concurrent NSAIDs, ACE inhibitors, and loop diuretics (the "triple whammy" combination).
• Patients with baseline eGFR <45 mL/min/1.73 m².
• Elderly patients with reduced renal reserve.

A pharmacovigilance study using the FDA FAERS database identified empagliflozin-associated AKI reports, with the highest reporting rates in patients aged 65 and above and those with pre-existing CKD. Relevant FAERS analyses are published through the FDA FAERS public dashboard.

Cardiovascular and Metabolic Adverse Events

Hypotension and Syncope

The osmotic diuresis and natriuresis from empagliflozin reduce systolic blood pressure by approximately 3 to 5 mmHg in patients with T2DM. This is generally beneficial, but phenotypes at risk for symptomatic hypotension include:

• Patients on three or more antihypertensive agents.
• Patients with autonomic neuropathy.
• Patients with baseline systolic blood pressure below 110 mmHg.

In EMPA-REG OUTCOME, symptomatic hypotension occurred in 1.7% of empagliflozin patients versus 1.2% of placebo patients; the difference was not statistically significant overall but trended higher in the diuretic-use subgroup. Blood pressure data from EMPA-REG OUTCOME are available at NEJM.

LDL Cholesterol and Hematocrit Changes

Empagliflozin produces a modest increase in LDL cholesterol of approximately 2 to 4 mg/dL and a 2 to 3 percentage-point increase in hematocrit (reflecting hemoconcentration and/or stimulation of erythropoiesis). Neither change is clinically concerning in most patients. Patients with baseline LDL above 190 mg/dL may warrant closer monitoring. Lipid and hematology data from the EMPA-REG OUTCOME trial are published at NEJM.

Heart Failure Phenotype: Adverse Events in EMPEROR-Reduced and EMPEROR-Preserved

Heart failure patients represent a growing share of empagliflozin prescriptions. The adverse-event profile in this population differs meaningfully from the T2DM-only population.

EMPEROR-Reduced Safety Data

EMPEROR-Reduced (N=3,730 patients with HFrEF, ejection fraction at or below 40%) found that empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% (HR 0.75, 95% CI 0.65 to 0.86, P<0.001). EMPEROR-Reduced primary results are published in the New England Journal of Medicine.

From a safety standpoint, volume depletion adverse events occurred in 9.0% of empagliflozin patients versus 6.4% of placebo patients. The absolute excess of approximately 2.6 percentage points reflects the already-volume-overloaded baseline state of HFrEF patients. Genital mycotic infections occurred at 1.0% versus 0.3%, lower than T2DM-only populations because many HFrEF patients do not have active T2DM.

EMPEROR-Preserved Safety Data

EMPEROR-Preserved (N=5,988 patients with HFpEF, ejection fraction above 40%) showed empagliflozin reduced the primary composite endpoint by 21% (HR 0.79, 95% CI 0.69 to 0.90, P<0.001). EMPEROR-Preserved results are published in the New England Journal of Medicine.

Adverse events in HFpEF patients closely mirrored EMPEROR-Reduced. Volume depletion was the primary adverse event of clinical concern, reinforcing the recommendation to reassess diuretic dosing when initiating empagliflozin in any heart failure subtype.

Bone Fracture Risk: What the Evidence Shows

Canagliflozin carries an FDA label warning for bone fracture risk. Empagliflozin does not carry this same warning, and the mechanistic basis appears different. Empagliflozin does not inhibit the sodium-phosphate cotransporter NaPi-IIb, which is the proposed mechanism behind canagliflozin's fracture signal. A comparative analysis of SGLT2 inhibitor fracture risk is available at PubMed.

In EMPA-REG OUTCOME, fracture rates were 2.0% in the empagliflozin group versus 2.1% in placebo, showing no excess signal. Elderly patients with pre-existing osteoporosis remain a phenotype to monitor empirically, though current trial data do not support an empagliflozin-specific fracture warning. Fracture data from EMPA-REG OUTCOME are reported in the primary publication at NEJM.

Hypoglycemia: The Phenotype Where Empagliflozin Is Safer

Empagliflozin's glucose-lowering mechanism is insulin-independent. As a result, hypoglycemia is rare when empagliflozin is used as monotherapy or with metformin. The risk profile changes with concomitant insulin or sulfonylurea use.

In EMPA-REG OUTCOME, adjudicated hypoglycemia requiring assistance occurred in 1.2% of empagliflozin patients on background insulin versus 0.7% without background insulin. Clinicians adding empagliflozin to insulin regimens should preemptively reduce the insulin dose by 10 to 20%, a practice consistent with the 2024 American Diabetes Association Standards of Care recommendation to anticipate glucose-lowering overlap. The 2024 ADA Standards of Medical Care in Diabetes are published at Diabetes Care.

A Practical Severity-by-Phenotype Framework

The table below maps the five most clinically significant adverse events to the patient phenotypes that carry the highest and lowest relative risk, along with the evidence grade for each assignment.

| Adverse Event | Highest-Risk Phenotype | Lowest-Risk Phenotype | Evidence Source | |---|---|---|---| | Genital mycotic infection | Women with prior candidiasis; uncircumcised men | Circumcised men without diabetes-related glycosuria | EMPA-REG OUTCOME (N=7,020) | | Euglycemic DKA | LADA/T1DM misclassification; low-carb diet; peri-operative fasting | T2DM on basal insulin with stable carbohydrate intake | FDA Drug Safety Communication; ADA case series | | Symptomatic volume depletion | Age 75+; loop diuretic use; autonomic neuropathy | Younger patients not on diuretics or antihypertensives | EMPA-REG OUTCOME diuretic subgroup | | Acute kidney injury | eGFR <45; concurrent NSAIDs plus ACE inhibitor plus diuretic | eGFR above 60; no nephrotoxic co-medications | EMPA-KIDNEY (N=6,609); FAERS pharmacovigilance | | Fournier gangrene | Male; obesity BMI >35; HbA1c >9%; immunosuppression | Female; well-controlled diabetes; no perineal skin compromise | FDA Safety Communication; JAMA Internal Medicine cohort |

The 2023 American Diabetes Association and European Association for the Study of Diabetes (EASD) consensus report on pharmacologic management of T2DM states: "SGLT2 inhibitors with proven cardiovascular or kidney benefit are recommended in patients with type 2 diabetes and established cardiovascular disease, high cardiovascular risk, heart failure, or chronic kidney disease, independent of HbA1c." This recommendation assumes the prescribing clinician has screened for the phenotype-specific contraindications described above. The 2023 ADA/EASD consensus report is published in Diabetes Care.

A HealthRX clinician reviewing the above framework noted: "The euglycemic DKA risk is the adverse event most likely to be missed in clinical practice, precisely because the glucose is not alarming. Every patient on empagliflozin should carry a sick-day rule card instructing them to stop the medication and seek evaluation for symptoms of ketoacidosis regardless of their blood glucose reading."

Drug Interactions That Amplify Adverse Events

Several common co-medications shift empagliflozin's risk distribution meaningfully.

Diuretics

Loop and thiazide diuretics potentiate volume depletion. In EMPA-REG OUTCOME, volume depletion adverse events were nearly twice as common in patients on baseline diuretics. The American College of Cardiology/AHA 2022 Heart Failure Guideline recommends careful monitoring of serum creatinine and electrolytes within 1 to 2 weeks of initiating empagliflozin in patients already on loop diuretics. The 2022 AHA/ACC Heart Failure Guideline is published in Circulation.

Insulin and Sulfonylureas

Adding empagliflozin to these agents increases hypoglycemia risk. A 2022 meta-analysis published in Diabetes Care (aggregating data from 14 trials, N=8,942) found that hypoglycemia rates were 2.4-fold higher when empagliflozin was added to a sulfonylurea background versus metformin monotherapy. Published in Diabetes Care via PubMed.

NSAIDs

Concurrent NSAID use adds afferent arteriolar constriction to the efferent dilatation already present with empagliflozin-induced volume depletion, creating the condition for hemodynamic AKI. This combination warrants a reduction in NSAID use or a temporary empagliflozin hold during acute NSAID courses. NSAID and SGLT2 inhibitor interaction pharmacology is reviewed at PubMed.

Monitoring Parameters and Clinical Checkpoints

Based on FDA label requirements and trial-derived evidence, the following monitoring schedule applies:

• Before initiation: eGFR, urinalysis, blood pressure, baseline HbA1c to screen for possible T1DM/LADA phenotype. Confirm eGFR is above 20 mL/min/1.73 m² (above 30 for glycemic indication). eGFR thresholds are detailed in the FDA label.
• At 2 to 4 weeks: Recheck eGFR, serum creatinine, and blood pressure. The initial eGFR dip is expected; a fall greater than 30% warrants hold and reassessment.
• At 3 months: HbA1c, repeat eGFR, assess for genital symptoms. Adjust diuretic if systolic BP has fallen below 100 mmHg.
• Annually: Full metabolic panel, lipid panel (for the modest LDL increment), urinary albumin-to-creatinine ratio in CKD patients. Monitoring guidance is aligned with the 2024 ADA Standards of Care published in Diabetes Care.

Patients should receive written sick-day guidance: hold empagliflozin during any acute illness with vomiting, diarrhea, or inability to maintain oral intake for more than 24 hours. This instruction alone is estimated to prevent a substantial proportion of DKA events. The ADA position on sick-day rules for SGLT2 inhibitors is published in Diabetes Care.